Acute Myeloid Leukemia (AML)
Presentation :
Pathophysiology :
Diagnostic Testing:
Treatment :
- Induction: 7+3 Regimen
- Venetoclax (Venclexta®) targets BCL-2 (also used in Chronic Lymphocytic Leukemia (CLL))
- Isocitrate Dehydrogenase (IDH) inhibitors:
- Enasidenib (Idhifa®) for IDH2 mutants.
- Ivosidenib (Tibsovo®) for IDH1 mutants
- CAR T cells
- Menin inhibitor:
- Revumenib (oral, selective inhibitor of the menin–KMT2A interaction):
- The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
- The prognosis of acute leukaemias harbouring rearrangements of the gene lysine methyltransferase 2A (KMT2A), previously known as mixed-lineage leukaemia (MLL), is poor, with a 5-year overall survival of less than 25%
- The interaction of menin with lysine methyltransferase 2A (KMT2A), an epigenetic regulator, is a dependence in acute leukaemia caused by either rearrangement of KMT2A or mutation of the nucleophosmin 1 gene (NPM1)
- Revumenib (oral, selective inhibitor of the menin–KMT2A interaction):
Prognosis:
References:
Created on: Wednesday 08-23-2023